PALATIN TECHNOLOGIES INC
10-K, EX-27, 2000-10-03
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: PALATIN TECHNOLOGIES INC, 10-K, EX-23, 2000-10-03
Next: STATEFED FINANCIAL CORP, DEF 14A, 2000-10-03



<TABLE> <S> <C>


<ARTICLE>                     5

<LEGEND>
This schedule contains summary financial information extracted from the
registrant's audited consolidated financial statements for the fiscal year ended
June 30, 2000 and is qualified  in its  entirety by reference to such  financial
statements.
</LEGEND>

<CURRENCY>                      U.S. Dollars


<S>                             <C>
<PERIOD-TYPE>                   Year
<FISCAL-YEAR-END>                              JUN-30-2000
<PERIOD-START>                                  JUL-1-1999
<PERIOD-END>                                   JUN-30-2000
<EXCHANGE-RATE>                                          1
<CASH>                                           3,129,593
<SECURITIES>                                     2,155,617
<RECEIVABLES>                                      953,163
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                 6,508,165
<PP&E>                                           1,573,140
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                   8,885,397
<CURRENT-LIABILITIES>                            1,012,070
<BONDS>                                                  0
                                    0
                                          7,336
<COMMON>                                            79,024
<OTHER-SE>                                       6,818,801
<TOTAL-LIABILITY-AND-EQUITY>                     8,885,397
<SALES>                                                  0
<TOTAL-REVENUES>                                 5,117,111
<CGS>                                                    0
<TOTAL-COSTS>                                   13,676,892
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                  29,247
<INCOME-PRETAX>                                 (8,183,438)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                             (8,183,438)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                    (8,183,438)
<EPS-BASIC>                                          (1.10)
<EPS-DILUTED>                                        (1.10)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission